Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies
-
By
-
Bo Xiang
-
Dongyi Zhao
-
Tao Liu
-
Guiying Xu
-
July 15, 2026
Clinical Scorecard: Sarcopenia's Role in Breast Cancer: Prognostic Implications and New Treatment Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Sarcopenia in Breast Cancer |
| Key Mechanisms | Progressive skeletal muscle loss affecting treatment tolerance and outcomes. |
| Target Population | Women diagnosed with breast cancer. |
| Care Setting | Oncological care, particularly in perioperative and neoadjuvant settings. |
Key Highlights
- Sarcopenia prevalence ranges from 12% to 49% in breast cancer patients.
- Low muscle mass predicts inferior survival and increased chemotherapy toxicity.
- Sarcopenia is potentially modifiable through multimodal interventions.
- Emerging pharmacological strategies target muscle health in cancer cachexia.
- Standardized assessment and prehabilitation trials are needed.
Guideline-Based Recommendations
Diagnosis
- Utilize imaging techniques such as CT, MRI, DEXA, or BIA for assessment.
Management
- Implement resistance training, protein optimization, and nutritional support.
Monitoring & Follow-up
- Regularly assess muscle mass and strength in breast cancer patients.
Risks
- Increased postoperative complications and reduced chemotherapy tolerance.
Patient & Prescribing Data
Women undergoing treatment for breast cancer.
Multimodal interventions show preliminary efficacy in preserving lean mass.
Clinical Best Practices
- Integrate muscle metrics with inflammatory indices for prognostic evaluation.
- Consider subtype-specific risk stratification for treatment planning.
- Encourage prehabilitation strategies to enhance muscle health preoperatively.
Related Resources & Content
